Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alfa-2a + retinoic acid
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Intramuscular, Oral
01
Overview
Interferon alfa-2a + retinoic acid is a combination therapy evaluated by the National Cancer Institute (NCI) in a Phase 2 pilot study for the treatment of lymphoproliferative disorders in children with congenital or acquired immunodeficiency syndromes, including HIV. Interferon alfa-2a is a recombinant type I interferon that binds to the IFNAR1/IFNAR2 receptor complex, triggering Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling to exert immunomodulatory, antiproliferative, and antiviral effects. Retinoic acid (initially 13-cis-retinoic acid/isotretinoin, later all-trans-retinoic acid/tretinoin) acts as a differentiating agent by binding to retinoic acid receptors (RARs), promoting the maturation of lymphoid cells and inhibiting their uncontrolled proliferation. This combination was specifically targeted at conditions like diffuse infiltrative lymphocytosis syndrome (DILS) and polyclonal B-cell lymphoproliferative disorders in immunocompromised patients.
- Brand names
- Roferon-A
- Other names
- interferon alfa-2a + 13-cis-retinoic acidinterferon alfa-2a + all-trans-retinoic acidRetinoic Acid and Interferon-Alpha2a
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)RARA (Retinoic acid receptor alpha)RARB (Retinoic acid receptor beta)RARG (Retinoic acid receptor gamma)RORB (RORβ / RORB)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on interferon alfa-2a + retinoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alfa-2a + retinoic acid.